Adham Salkeni, MD retweeted
Did you also learn in the past that IL-10 would promote an immunosuppressive TME? This review shows it can have also anti-tumor effect. Congratulations to @AdhamSalkeni for the publication. – at Houston, TX
Interleukin-10 in cancer immunotherapy: from bench to bedside: bit.ly/3CGWEup by Dr. Adham Salkeni @AdhamSalkeni @theNCI & @ANaingMD @MDAndersonNews published @trendscancer @CellPressNews c/c @OncoAlert
Adham Salkeni, MD retweeted
Interleukin-10 in cancer immunotherapy: from bench to bedside: bit.ly/3CGWEup by Dr. Adham Salkeni @AdhamSalkeni @theNCI & @ANaingMD @MDAndersonNews published @trendscancer @CellPressNews c/c @OncoAlert
Adham Salkeni, MD retweeted
4.Do promotion committees seriously consider or promote physicians and scientists who have published their research projects with negative results as much as those who have published their projects with positive results?
24%Yes
76%No
17 votes • Final resultsDo you know or treat someone w ➡️Nonconventional⬅️#chondrosarcoma (dedifferentiated/clear cell/mesench)? INBRX-109 (DR5 agonist) yielded remarkable activity (67% tumor regressions) in an early report. INBRX-109 clinical trial open @ NEXT-Virginia. #sarcoma #oncology
RT & amplify
1
Adham Salkeni, MD retweeted
My team is pleased to report the initial findings of the translational work of a combination of NT-I7 @NeoImmuneTech plus Pembro @sitcancer by @ANaingMD et al @MDAndersonNews @MoffittNews c/c @PatrickHwuMD @OncoAlert @weoncologists @SewantiLimaye @doctorpemm
Findings from the lab of our Dr. Aung Naing suggest NT-17 can boost T cell infiltration and immunotherapy responses in immunologically cold tumors.
Naing presents the findings at #SITC22: https://nitter.cf/t.co/uzP98FDWbt @ANaingMD #EndCancer
Adham Salkeni, MD retweeted
If I can get the smart algorithms of Twitter to stop showing me tweets about: @elonmusk , verification, blue check, 8$, covid, or elections, I will be a very happy man!!
Some second/third line therapies have pathetic response rates - single digits ➡️ Refer for a clinical trial.. #oncology #MedTwitter
3
Kudos to all trial designers that allow intrapatient dose escalation.. should be the norm not the exception #phase1 #oncology #MedTwitter
































